Insurer strategies to control costs associated with weight loss drugs By Justin Lo and Cynthia Cox KFF

https://www.healthsystemtracker.org/brief/insurer-strategies-to-control-costs-associated-with-weight-loss-drugs/ A class of drugs called GLP-1 agonists, which includes Ozempic (semaglutide), has been used to treat type 2 diabetes for over a decade. Due to their potential to trigger weight loss, focus on these drugs has shifted in application to obesity, with new drug products using these same ingredients gaining FDA approval for such treatment. A recent nationwide estimate of obesity indicated that 42% of adults aged 20 and over are obese. Demand may continue to increase as more GLP-1 agonists are approved for other conditions, such as preventing heart attacks or strokes in adults with cardiovascular disease.